and spending on cardiovascular medications in Canada. Regular surveillance of such trends is important to determine whether medications that reduce morbidity and mortality appropriately dominate the landscape, to identify interprovincial differences in drug use and to inform policy-makers who need to consider the cost trends for future planning.
Methods
Study design and data source We conducted a population-level observational cohort study using data from IMS Health Canada's CompuScript Audit ® database. CompuScript is a source of prescription data obtained by measuring, through an audit, the number and estimated value of prescriptions dispensed from Canadian retail pharmacies (includes markups and professional fees). The CompuScript sample is drawn from the IMS prescription database panel, which comprises over 5000 pharmacies, representing about two-thirds of all retail pharmacies in Canada. The CompuScript panel encompasses more than 2700 stores, each stratified by province, type (chain, independent or banner) and size (large or small). Nonidentifiable electronic extracts from records of dispensed prescriptions are collected monthly from each of these pharmacies. After passing through various quality-control checks, the sample data are projected to the "universe" in each province, and provincial totals are summed to generate a national estimate. The data collected can be used to ascertain prescription volume by drug class and the market share for trending purposes, providing a measure of product utilization. Also available is the cost of the prescription as dispensed (including all markups and the pharmacist's professional fee). For this study, we used data for the period February 1996 to December 2006. The IMS Health Canada database records aggregate population-wide data rather than patient-specific data.
Analysis
We used descriptive statistics to report the data on utilization of cardiovascular medications. The specific cardiovascular medication classes of interest were oral anticoagulants, thienopyridine antiplatelet agents, nitroglycerin, β-blockers, calcium antagonists, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers, diuretics and statins (Appendix 1, available at www.cmaj. ca/cgi /content /full /cmaj .081913/DC2). For each class of medications, we described trends for the number of prescriptions, the total expenditures for prescription claims (as extrapolated to the total population) and changes in expenditures over time. We used monthly utilization data to illustrate the changing trends for each medication class, at a national level, over the 11-year study period. Combination products of β-blockers, ACE inhibitors or angiotensin-receptor blockers with diuretics were included in the total numbers for each individual drug product. For interprovincial comparisons of drug use, we used expenditures as a proxy for the total number of prescriptions dispensed. We did this to minimize variability and hence misclassification errors due to differing frequency of prescription refills between provinces. We compared medication expenditures per 100 000 population across provinces, using 2001 Canadian census data for population estimates, to detect any geographic variation. 24 We also compared changes in medica- 
Results
The number of prescriptions for all cardiovascular medication classes increased over the study period, with the exception of nitroglycerin products, for which utilization declined ( Figure  1) Table 1 of the full-text version, available at www .cmaj .ca /cgi /content /full/cmaj.081913). In 2006, total costs of cardiovascular medications exceeded $5 billion, with statins accounting for nearly 40% of this spending. As of 2006, the cardiovascular medication classes associated with the highest expenditures were statins, ACE inhibitors and calcium antagonists, in that order. The same drugs accounted for the highest expenditures in 1996, but the order was calcium antagonists, ACE inhibitors and statins (see Figure 3 of the full-text version of this article, available at www.cmaj.ca /cgi /content /full /cmaj.081913). In 2006, calcium antagonists were the fifth highest medication class by utilization, but they represented the third highest medication class for expenditures. Nationwide, angiotensin-receptor blockers were associated with the highest annual rate of increase in expenditures and, given current trends, may soon surpass calcium antagonists and ACE inhibitors in their proportionate contribution to overall expenditures.
The number of prescriptions for antihypertensive drug classes (β-blockers, calcium antagonists, ACE inhibitors, angiotensin-receptor blockers and diuretics) rose by 136% from 1996 to 2005, and associated expenditures rose by 141% during the same period. Even after adjustment for the 91% increase in the number of Canadians with hypertension during the study period, the annual cost of antihypertensive prescriptions per individual with hypertension increased by 19.4%. 25, 26 Contributors to this increase may also include the 15. 
Variations in total expenditures by province
Between 1996 and 2006, the total expenditures for cardiovascular medications dispensed per 100 000 population varied by province. In 2006, total expenditures were lowest in the western provinces and highest in Quebec, New Brunswick and Nova Scotia (see Figure 3 of this version). We also observed variation in provincial expenditures when we analyzed the data by individual medication class (see Appendix 2, available at www.cmaj. ca/cgi /content /full /cmaj.081913/DC2). In 2006, expenditures were highest for statins and secondhighest for ACE inhibitors in all provinces except Quebec, where calcium antagonists represented the second-highest expenditure. Quebec had the highest per capita expenditures for 4 of the 9 cardiovascular medication classes examined (statins, angiotensin-receptor blockers, diuretics and sublingual nitroglycerin), whereas New Brunswick had the highest per capita expenditures for ACE inhibitors, nitroglycerin and calcium antagonists. For all but 3 cardiovascular medication classes, the lowest per capita expenditure occurred in 1 of the 3 westernmost provinces (British Columbia, Alberta or Saskatchewan). The exceptions were angiotensin-receptor blockers and anticoagulants, for which the provinces of Newfoundland and Labrador, and Prince Edward Island (combined) had the lowest expenditures, and ACE inhibitors, for which Quebec had the lowest expenditures.
There was moderate variation in the rank order of per capita expenditures by medication class within each province in 2006. However, expenditures for those prescriptions varied by more than 2-fold for 4 of the 9 cardiovascular medication classes evaluated.
In 2006, the ratio of highest to lowest provincial per capita expenditures was 2 or more for nitroglycerin (2.6), angiotensin-receptor blockers (2.1), statins (2.1) and β-blockers (2.0) (see Appendix 2), which represents high inter- provincial variability in expenditures for these cardiovascular medications.
Temporal changes in expenditures by province
When we compared the first half of the study period (1996-2001) with the second half (2002-2006), we found distinct patterns regarding changes in per capita expenditures for cardiovascular medications by province (see Table 1 of this version). By far the greatest increases in expenditures were for angiotensin-receptor blockers and thienopyridines, with increases for angiotensin-receptor blockers exceeding 300% in all pro vinces. This pair of drug classes was followed by statins, for which expenditures increased by more than 120% in all provinces. For most provinces, increases were small to moderate, between 1% and 99%, for ACE inhibitors, diuretics, calcium antagonists, β-blockers and anticoagulants. In most provinces, there was a decline in expenditures associated with nitroglycerin prescriptions dispensed over the study period. Increases in expenditures for most medication classes were greater in the western Canadian provinces than the eastern provinces. Manitoba had the highest or second highest increases in per capita spending for 6 of the 10 medication classes evaluated.
Interpretation
In this population-based study, we observed a sharp and steady increase in the use of and expenditures for cardiovascular medications in Canada, with expenditures increasing more than 200% over the decade of study. Cardiovascular medications are the most commonly prescribed drugs in Canada, representing 1 of every 5 prescriptions. 27 Expenditures for these drugs are far outpacing overall increases in drug costs and international growth rates for expenditures on cardiovascular drugs from the decade preceding our study.
28
A recent Canadian report 3 found that between 1994 and 2004, expenditures on all prescription drugs increased by 97%, meaning that the rate of increase in costs for cardiovascular medications was more than twice that estimated for all medication expenditures in Canada. 3, 27, 29 A report of cardiovascular drug use in 12 countries of the Organisation for Economic Co-operation and Development 28 cited average annualized growth in expenditures of 6.2% between 1989 and 1999.
We observed no plateau in spending on cardiovascular medications in Canada during the study period. If expenditures continue to increase at these rates, annual costs for cardiovascular medications alone will reach about $10.6 billion in Canada by 2020. In 2007, Canadians spent 17 cents of every health care dollar on medication costs, which represented a 16% increase in proportional health care spending since 1997. 29 This rapid escalation in costs for cardiovascular drugs threatens the sustainability of public drug insurance programs. Increases of this magnitude over such a relatively short period deserve further scrutiny.
Increases in the use of cardiovascular medications over time may be explained by changes in demographic characteristics and risk factor profiles of the Canadian population and changes in the economy, as summarized in Table 3 of the full-text version of this article (available at www.cmaj.ca /cgi /content /full/cmaj.081913). From 1996 to 2006, pharmaceutical-specific inflation in Canada increased by about 11%, which might have contributed to the increased expenditures. 30 The Canadian Institute for Health Information has reported that, although total population growth in Canada is about 1.1% annually, the growth has been gradual and was unlikely to account for increases in overall drug expenditures. 29 Cardiovascular disease is more prevalent with age, and older people are therefore more likely to require cardiovascular medications. During our study period, the proportion of the Canadian population older than 65 years increased by about 9%. 24 Self-reported surveys of risk factors in the Canadian population over time have revealed that prevalence rates of diabetes and hypertension increased dramatically over the decade of our study, whereas rates of obesity increased moderately and smoking rates declined. 31 Escalating rates of hypertension may explain increased use of antihypertensive medications in Canada, but not increased use of other medication classes. Overall, these demographic, population and economic factors potentially explain 136% or two-thirds of the increase in cardiovascular medication expenditures that we observed.
The mean cost of an individual cardiovascular prescription increased by 14.2% between 1996 and 2006, but overall growth in expenditures for cardiovascular medications exceeded 200%. Given that the prices of individual drugs have been relatively stable over the last decade, increases in drug costs are more likely due to increased prescription volume, as determined by the potentially influential factors previously described, and to an increase in the use of newer, more expensive medications. 29, 32 We observed that the use of newer medication classes, such as angiotensin-receptor blockers and statins, increased at a faster rate than the use of older medication classes, such as diuretics and β-blockers. The use of patented (or brand name) medications as a proportion of sales of all prescription drugs in Canada increased by 58% in the study period, from 45% in 1996 to 71% in 2006. 33 This transition to greater use of patented medications, which tend to be more expensive than nonpatented (generic) medications, potentially explains about 60% of the increased expenditures that we observed. 29, 33 Scrutiny of this shift is warranted, particularly where a class effect has been demonstrated, since older, more established and hence less expensive medications may be the most cost-effective option. 34, 35 Between 1996 and 2006, an average of 88 new patented drugs were made available annually in Canada, with only 20%-25% of these representing new active substances. 33 This means that many of the new brand name medications may not represent major therapeutic advances. Morgan and colleagues 36 recently studied overall drug expenditures in one Canadian province, British Columbia, and found that 80% of the increases in drug costs were due to use of new patented medications that were not considered to offer an important therapeutic advantage.
The costs of generic drugs may also be contributing to rising cardiovascular drug costs. The median price of generic drugs is higher in Canada than in 11 other developed countries. 37 The National Pharmaceutical Strategy noted that if Canada had not exceeded the international median price for generic drugs in 2005, the country could have saved $1.5 billion in medication costs during that year. Given that cardiovascular medications account for about 20%-25% of all drug costs, a saving of about $350 million per year could have accrued from more controlled pricing within this group of drugs alone. 38 We found that the medication classes with the greatest increases in number of prescriptions dispensed and associated expenditures were angiotensin-receptor blockers, antiplatelet agents, statins and ACE inhibitors. Many of the medications in these classes are brand name drugs, particularly for an- However, whether these drugs should be replacing older, established medications is debatable. 34, 35 The recommendations in hypertension guidelines, which have traditionally favoured relatively cheaper diuretics and β-blockers as first-line therapies, have been revised over the years to include more expensive ACE inhibitors, angiotensin-receptor blockers and calcium antagonists as possible first-line agents. There is also an increasing trend for recommending combination therapy if there is only a partial response to monotherapy, whereas previous recommendations suggested dose escalation or switching to an alternative monotherapy if the initial treatment was only partially effective. 19, 20 These guideline changes, along with the increasing prevalence of hypertension in Canada, may have influenced the increased use of antihypertensive medications, particularly newer, more expensive agents, such as ACE inhibitors and angiotensin-receptor blockers. 39 Total per capita spending on cardiovascular prescriptions differed across the provinces by about 50%, representing variability in expenditures for cardiovascular medications across Canada. Variability was especially high for the newer medication classes, such as angiotensin-receptor blockers and statins. We found a descending east-to-west gradient in the use of and attendant cost for cardiovascular medications, with higher rates of both use and expenditures in eastern Canada. The prevalence of cardiac risk factors and overt cardiovascular disease has been found to have a east-to-west gradient, with higher rates in the east. 40 Potentially, then, some of the increased use may appropriately reflect greater clinical need. Quebec, New Brunswick and Nova Scotia had higher per capita expenditures for cardiovascular drugs than the other provinces. Our observation of Quebec's higher expenditures for cardiovascular medications is consistent with a 2007 report on drug expenditures from the Canadian Institute for Health Information, which showed that Quebec had the highest total drug costs as a proportion of total health expenditures among all Canadian provinces. 27 In contrast to the descending east-to-west gradient for cumulative total cardiovascular drug expenditures from 1996 to 2006, we found a predominantly inverse west-to-east gradient for relative increases in use and expenditures for cardiovascular medications between 1996-2001 and 2002-2006; these increases were greatest for western Canada. Thus, although the western provinces initially seemed more frugal than the eastern provinces in their use of and expenditures for cardiovascular medications, they experienced a "catchup" during the second half of the study period. One factor driving higher rates of prescriptions and costs in the west may be the proliferation of the Internet pharmacy business in Manitoba, which experienced among the highest recent increases of any province. Despite this extraneous factor influencing cardiovascular drug expenditures, other western provinces, most notably British Columbia, had some of the highest rates of increase for several classes of cardiovascular medications, even though they had the lowest expenditures in the earlier period. Further exploration of interprovincial variability in rates of increase for cardiovascular drug expenditures is warranted to identify underlying causes for the observed regional differences. Potential factors include differences in demographic characteristics, risk factors, drug policies or responses to national pharmaceutical initiatives, such as participation in the Common Drug Review.
Research

Limitations
Our study had some limitations. IMS Health Canada uses data collected from audits of prescriptions dispensed to describe general trends in drug utilization. As such, these data do not reflect exact drug utilization by individual patients or providers to determine the appropriateness of drug use. We did not have access to clinical data, such as medical conditions, blood pressure or cholesterol levels, to determine whether the prescribing of these medications was clinically appropriate. Although we observed increased use of cardiovascular medications, we could not evaluate the effects on patient outcomes and cost-effectiveness. Despite these limitations, these data provided a nationally representative sample of prescriptions, allowing us to highlight important national and provincial trends in the use of cardiovascular medications and associated spending.
Conclusion
Prescriptions and expenditures for cardiovascular medications escalated over the period 1996 to 2006 in Canada. Projected increases may reach potentially unsustainable levels. Although many demographic, economic and population factors may have contributed to these increases, newer classes of cardiovascular medications represented a large driver of escalating use and costs, contributing to substantial interprovincial variability in medication use. Given the magnitude of growth of the expenditures involved, ensuring the prescribing of costeffective medications is essential.
